Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Care Specialists program Help your members on high-cost clinical drugs Insert Link Help members and their prescribers make better decisions about medicines through this clinical intelligence hub...

Reimagine your pharmacy benefit partner Get expert insights Go Somewhere Save, Simplify, Support™ Biologic drugs are transforming lives for the better, yet often at a substantial cost. Biosimilars,...

Cover image Specialty insights to watch Prime Therapeutics /summer-2026-prime-therapeutics-report The Summer 2026 Prime Therapeutics Report delivers practical insights on the therapies, trends and...

research 10 research posters presented by Prime at AMCP Nexus 2024 Studies include Prime’s GLP-1 obesity research, health equity, and real world case studies Evaluating the 10-Year Impact of an...

Oncology Insights Oncology Case Management and Navigation: How do they differ? Caring for and treating a patient with cancer is complex. Many patients struggle to coordinate therapy, manage...

50M Footnotes As many as 50M people in the United States have an autoimmune disease, making it the third most prevalent disease category, surpassed only by cancer and heart disease.2 Unlock...

Weight loss Support and empower weight loss in a healthy, manageable and sustainable way with customized paths for each member. Medication management Improve drug adherence or reduce the number of...

Flexible, cost-effective, strategic partnership Specialty drugs have changed the pharmacy landscape over the past decade and now represent more than half of total drug spend. Having a strong...

High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...

Insert Link Medical Formulary Strategy ensures the most appropriate and clinically effective medical benefit drugs are evaluated with product-preferencing strategies, for all lines of business....

For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

May 22, 2025 – mepolizumab (Nucala) GlaxoSmithKline; an IL-5 antagonist monoclonal antibody New indication: add-on maintenance treatment of adults with inadequately controlled chronic obstructive...

Clinical deep dive Disease state overview WAS is a rare, X-linked, genetic disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmunity and...

Medication Nonadherence Social Determinants of Health Risk Score: Development and Use 2024 AMCP Annual Posters Real-World First Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1...

All brand names are property of their respective owners. References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560...

Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...

Speaking Engagements Learn more Yuqian Liu and Camile Rabe & Tim O'Shea, Horizon Mission Impossible: How Integrated Medical & Pharmacy Benefits Can Improve Specialty Drug Management with Prime's...

Marquee event showcased new Prime, our energy, ambition and transformative journey

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs